H. Lundbeck A/S - Product Pipeline Review - 2014

Date: May 21, 2014
Pages: 59
Price:
US$ 1,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: H8C1B9C128CEN
Leaflet:

Download PDF Leaflet

H. Lundbeck A/S - Product Pipeline Review - 2014
Summary

Global Markets Direct’s, ‘H. Lundbeck A/S - Product Pipeline Review - 2014’, provides an overview of the H. Lundbeck A/S’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of H. Lundbeck A/S’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of H. Lundbeck A/S including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of H. Lundbeck A/S’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the H. Lundbeck A/S’s pipeline products
Reasons to buy
  • Evaluate H. Lundbeck A/S’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of H. Lundbeck A/S in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the H. Lundbeck A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of H. Lundbeck A/S and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of H. Lundbeck A/S
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
  • Explore the dormant and discontinued projects of H. Lundbeck A/S and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
H. Lundbeck A/S Snapshot
H. Lundbeck A/S Overview
Key Information
Key Facts
H. Lundbeck A/S - Research and Development Overview
Key Therapeutic Areas
H. Lundbeck A/S - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Partnered Products
Partnered Products/Combination Treatment Modalities
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
H. Lundbeck A/S - Pipeline Products Glance
H. Lundbeck A/S - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
H. Lundbeck A/S - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
H. Lundbeck A/S - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
H. Lundbeck A/S - Drug Profiles
carbamazepine
Product Description
Mechanism of Action
R&D Progress
vortioxetine hydrobromide
Product Description
Mechanism of Action
R&D Progress
desmoteplase
Product Description
Mechanism of Action
R&D Progress
LuAE-58054
Product Description
Mechanism of Action
R&D Progress
LuAF-11167
Product Description
Mechanism of Action
R&D Progress
tedatioxetine
Product Description
Mechanism of Action
R&D Progress
KW-6356
Product Description
Mechanism of Action
R&D Progress
LUAF-20513
Product Description
Mechanism of Action
R&D Progress
LUAF-64280
Product Description
Mechanism of Action
R&D Progress
Phosphodiesterase 10A Inhibitors
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit LRRK-2 for Parkinson's Disease
Product Description
Mechanism of Action
R&D Progress
H. Lundbeck A/S - Pipeline Analysis
H. Lundbeck A/S - Pipeline Products by Target
H. Lundbeck A/S - Pipeline Products by Route of Administration
H. Lundbeck A/S - Pipeline Products by Molecule Type
H. Lundbeck A/S - Pipeline Products by Mechanism of Action
H. Lundbeck A/S - Recent Pipeline Updates
H. Lundbeck A/S - Dormant Projects
H. Lundbeck A/S - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
gaboxadol
LuAA-47070
Lu-02750
Lu-35138
Lu-AA24493
LuAA-37096
LuAA-38466
LuAA-39959
LuAA-44608
LuAE-04621
LuAE-58054
ORE-10002
siramesine
H. Lundbeck A/S - Company Statement
H. Lundbeck A/S - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

H. Lundbeck A/S, Key Information
H. Lundbeck A/S, Key Facts
H. Lundbeck A/S - Pipeline by Indication, 2014
H. Lundbeck A/S - Pipeline by Stage of Development, 2014
H. Lundbeck A/S - Monotherapy Products in Pipeline, 2014
H. Lundbeck A/S - Partnered Products in Pipeline, 2014
H. Lundbeck A/S - Partnered Products/ Combination Treatment Modalities, 2014
H. Lundbeck A/S - Out-Licensed Products in Pipeline, 2014
H. Lundbeck A/S - Out-Licensed Products/ Combination Treatment Modalities, 2014
H. Lundbeck A/S - Pre-Registration, 2014
H. Lundbeck A/S - Phase III, 2014
H. Lundbeck A/S - Phase II, 2014
H. Lundbeck A/S - Phase I, 2014
H. Lundbeck A/S - Preclinical, 2014
H. Lundbeck A/S - Discovery, 2014
H. Lundbeck A/S - Pipeline by Target, 2014
H. Lundbeck A/S - Pipeline by Route of Administration, 2014
H. Lundbeck A/S - Pipeline by Molecule Type, 2014
H. Lundbeck A/S - Pipeline Products by Mechanism of Action, 2014
H. Lundbeck A/S - Recent Pipeline Updates, 2014
H. Lundbeck A/S - Dormant Developmental Projects,2014
H. Lundbeck A/S - Discontinued Pipeline Products, 2014
H. Lundbeck A/S, Subsidiaries

LIST OF FIGURES

H. Lundbeck A/S - Pipeline by Top 10 Indication, 2014
H. Lundbeck A/S - Pipeline by Stage of Development, 2014
H. Lundbeck A/S - Monotherapy Products in Pipeline, 2014
H. Lundbeck A/S - Partnered Products in Pipeline, 2014
H. Lundbeck A/S - Pipeline by Top 10 Target, 2014
H. Lundbeck A/S - Pipeline by Top 10 Route of Administration, 2014
H. Lundbeck A/S - Pipeline by Top 10 Molecule Type, 2014
H. Lundbeck A/S - Pipeline Products by Top 10 Mechanism of Action, 2014
PAION AG - Product Pipeline Review - Q4 2010 US$ 500.00 Nov, 2010 · 42 pages
PAION AG – Product Pipeline Review – Q1 2011 US$ 500.00 Mar, 2011 · 42 pages

Ask Your Question

H. Lundbeck A/S - Product Pipeline Review - 2014
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: